Ly K Ina, Wen Patrick Y, Huang Raymond Y
Stephen E. and Catherine Pappas Center for Neuro-Oncology, Yawkey 9E, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Neurol Clin. 2020 Feb;38(1):95-113. doi: 10.1016/j.ncl.2019.08.004. Epub 2019 Nov 7.
The 2016 World Health Organization Classification of Tumors of the Central Nervous System (CNS) incorporated well-established molecular markers known to drive tumorigenesis and tumor behavior into the existing classification of CNS tumors based on histopathologic appearance. This integrated classification system has led to a major restructuring of the diffuse gliomas. In addition, it resulted in the categorization of medulloblastomas into four distinct molecular subgroups. Radiogenomic studies have revealed key imaging differences between certain genetic groups and may aid in the diagnosis, longitudinal assessment of treatment response, and evaluation of tumor recurrence in patients with brain tumors.
2016年世界卫生组织中枢神经系统（CNS）肿瘤分类将已知驱动肿瘤发生和肿瘤行为的成熟分子标志物纳入基于组织病理学外观的现有CNS肿瘤分类中。这种综合分类系统导致了弥漫性胶质瘤的重大重组。此外，它还将髓母细胞瘤分为四个不同的分子亚组。放射基因组学研究揭示了某些基因组之间的关键影像学差异，可能有助于脑肿瘤患者的诊断、治疗反应的纵向评估以及肿瘤复发的评估。
